Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1839154 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL11902437 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL14550059 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL1839151 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL1019425 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL34467094 | 0.87 | MAPT (0.53) | SLC9A1FFAR1MAPTGAAHPGD | |
| SCHEMBL16232154 | 0.84 | SLC9A1 (0.60) | SLC9A1HRH3KDM1ASIGMAR1MAPT | |
| SCHEMBL17189659 | 0.84 | SLC9A1 (0.65) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL13976000 | 0.84 | SLC9A1 (0.65) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL12765396 | 0.84 | SLC9A1 (0.60) | SLC9A1HRH3KDM1ASIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559902-A2 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3256218-B1 | A KDM1A INHIBITOR AND ITS USE IN THERAPY | IMAGO BIOSCIENCES INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220073477-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| CN-112312902-B | Pd (II) -catalyzed enantioselective C-H arylation of free carboxylic acids | 斯克里普斯研究学院 | 2022-02-18 | — | — | CN | disclosed |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| CN-107427699-B | KDM1A inhibitors for the treatment of disease | 伊美格生物科学公司 | 2021-10-19 | — | — | CN | disclosed |
| US-11021427-B2 | Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021427-B2 | Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210087131-A1 | PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE | 2021-03-25 | — | — | US | disclosed |
| US-20210087131-A1 | PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE | 2021-03-25 | — | — | US | disclosed |
| US-20200283397-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| WO-2019204477-A1 | PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20180312474-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2018-11-01 | — | — | US | disclosed |
| US-9981922-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2017165822-A1 | SMALL MOLECULE INHIBITOR OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20090036473-A1 | NOVEL QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036473-A1 | NOVEL QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | KCNK17, KCNN3, KCNA7 | SLC9A1 263/4885FFAR1 2816/4885HRH3 1085/4885 |
| US-20200283397-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | SLC9A1 3240/4885FFAR1 4334/4885HRH3 1345/4885 |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | SLC9A1 3240/4885FFAR1 4334/4885HRH3 1345/4885 |
| US-20180312474-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | SLC9A1 3240/4885FFAR1 4334/4885HRH3 1345/4885 |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | SLC9A1 3240/4885FFAR1 4334/4885HRH3 1345/4885 |
| US-20220073477-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | SLC9A1 3240/4885FFAR1 4334/4885HRH3 1345/4885 |
| US-11021427-B2 | Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids | PDCD1, PDK3, PDCD1LG2 | SLC9A1 2367/4885FFAR1 119/4885HRH3 49/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | SLC9A1 3240/4885FFAR1 4334/4885HRH3 1345/4885 |
| US-20210087131-A1 | PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS | PDCD1, PDK3, PDCD1LG2 | SLC9A1 2369/4885FFAR1 124/4885HRH3 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.